Jonathan Leiken - 08 Mar 2022 Form 4 Insider Report for DIEBOLD NIXDORF, Inc (DBD)

Role
EVP, CLO and Secretary
Signature
Jonathan B. Leiken
Issuer symbol
DBD
Transactions as of
08 Mar 2022
Net transactions value
$0
Form type
4
Filing time
10 Mar 2022, 15:30:14 UTC
Previous filing
08 Feb 2022
Next filing
12 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DBD Common Shares Award $0 +127,864 +93% $0.000000 264,708 08 Mar 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DBD Non-Qualified Stock Option 21,397 08 Mar 2022 Common Shares 21,397 $32.33 Direct F3
holding DBD Non-Qualified Stock Option 24,581 08 Mar 2022 Common Shares 24,581 $27.39 Direct F3
holding DBD Non-Qualified Stock Options 46,875 08 Mar 2022 Common Shares 46,875 $26.60 Direct F3
holding DBD Non-Qualified Stock Option 24,517 08 Mar 2022 Common Shares 24,517 $18.75 Direct F4
holding DBD Non-Qualified Stock Option 43,715 08 Mar 2022 Common Shares 43,715 $4.08 Direct F4
holding DBD Non-Qualified Stock Option 12,048 08 Mar 2022 Common Shares 12,048 $11.96 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of restricted stock units; each restricted stock unit represents a contingent right to receive one share of Diebold Nixdorf, Incorporated common stock.
F2 Number includes restricted stock units.
F3 Granted under the 1991 Equity and Performance Incentive Plan; option is generally exercisable in annual increments of 1/3, 1/3, 1/3 beginning one year from the date of grant.
F4 Granted under the 2017 Equity and Performance Incentive Plan; option is generally exercisable in annual increments of 1/3, 1/3, 1/3 beginning one year from the date of grant.